Analysts forecast that Neon Therapeutics Inc (NASDAQ:NTGN) will announce earnings per share (EPS) of ($0.67) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Neon Therapeutics’ earnings, with estimates ranging from ($0.70) to ($0.64). The firm is scheduled to issue its next quarterly earnings results on Monday, February 11th.
According to Zacks, analysts expect that Neon Therapeutics will report full year earnings of ($5.17) per share for the current financial year, with EPS estimates ranging from ($5.50) to ($4.84). For the next financial year, analysts forecast that the firm will post earnings of ($3.06) per share, with EPS estimates ranging from ($3.44) to ($2.70). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings results on Monday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.12.
Several large investors have recently modified their holdings of the company. TRV GP Iii LLC acquired a new stake in shares of Neon Therapeutics in the 2nd quarter valued at $122,745,000. FMR LLC acquired a new stake in shares of Neon Therapeutics in the 2nd quarter valued at $26,746,000. Partner Fund Management L.P. acquired a new stake in shares of Neon Therapeutics in the 2nd quarter valued at $10,771,000. Partner Investment Management L.P. boosted its stake in shares of Neon Therapeutics by 32,903.8% in the 3rd quarter. Partner Investment Management L.P. now owns 832,355 shares of the company’s stock valued at $5,841,000 after purchasing an additional 829,833 shares in the last quarter. Finally, Hillhouse Capital Management Ltd. acquired a new stake in shares of Neon Therapeutics in the 2nd quarter valued at $8,969,000. Institutional investors own 71.09% of the company’s stock.
Neon Therapeutics stock traded down $0.15 on Monday, hitting $5.73. The company’s stock had a trading volume of 67,857 shares, compared to its average volume of 87,450. Neon Therapeutics has a one year low of $5.51 and a one year high of $16.23.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Article: Momentum Indicator: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.